GlassScriptPhysician profile
Ivey Madelyn Walker
NPI 1215678487
$5,724.63
in general payments reported to CMS, 2019-2025
30 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $1,512 · 2024: $1,248 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,728 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $451 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,727.90 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $450.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,300.69 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $688.53 | 2023-2025 | Myrisk |
| Daiichi Sankyo INC. | $587.37 | 2023-2025 | Enhertu |
| Janssen Biotech, INC. | $447.03 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Stemline Therapeutics INC. | $371.03 | 2023-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $326.43 | 2022-2025 | Jaypirca, Verzenio |
| Incyte Corporation | $304.16 | 2022-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $239.11 | 2023-2025 | Enhertu |
| Gilead Sciences, INC. | $161.16 | 2023-2025 | Trodelvy |
| Pfizer INC. | $154.71 | 2023-2025 | |
| Abbvie INC. | $137.40 | 2023-2025 | |
| Genmab U.S., INC. | $109.84 | 2024 | Epkinly |
| Astellas Pharma US INC | $99.00 | 2023 | |
| G1 Therapeutics, INC. | $95.36 | 2022 | |
| Pharmaessentia USA Corporation | $94.57 | 2023 | Besremi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $82.70 | 2022-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $69.18 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $53.66 | 2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $51.39 | 2023-2025 | Ojjaara |
| Karyopharm Therapeutics INC. | $48.33 | 2025 | Xpovio |
| Amgen INC. | $46.67 | 2023 | Nplate, Vectibix, Xgeva |
| Eisai INC. | $43.32 | 2022-2023 | |
| Beigene USA, INC. | $37.55 | 2024-2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $33.90 | 2023 | Welireg, Keytruda |
| Array Biopharma INC | $27.88 | 2025 | Tukysa, Braftovi, Mektovi |
| Sobi, INC | $27.55 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.69 | 2024 | |
| Agios Pharmaceuticals, INC. | $21.26 | 2024 | Pyrukynd |
| Secura Bio, INC. | $19.76 | 2024 | Copiktra |
| Fennec Pharmaceuticals, INC. | $19.40 | 2025 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivey Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.